Abstract
Lifestyle modifications and optimization of the management of cardiometabolic comorbidities are currently the mainstay of treatment for patients with nonalcoholic fatty liver disease. Pharmacotherapy to halt or reverse hepatic histological injury and prevent the development of end-stage liver disease is specifically offered to patients with nonalcoholic steatohepatitis (NASH) and those with advanced fibrosis. In this review, the authors discuss the state of the art of various pharmacological agents for NASH. The efficacy of vitamin E and pioglitazone is reasonably well established in a selected group of patients with NASH. Current data do not offer convincing evidence for efficacy of pentoxifylline, long-chain polyunsaturated fatty acids, angiotensin receptor blockers, metformin, or ursodeoxycholic acid. They also discuss the state of several emerging agents for treating NASH including the farsenoid X receptor ligand, obeticholic acid.
Keywords
Obeticholic acidPioglitazoneMedicineNonalcoholic fatty liver diseasePharmacotherapyUrsodeoxycholic acidMetforminInternal medicinePharmacologyGastroenterologyDiseaseFatty liverEndocrinologyType 2 diabetesDiabetes mellitusReceptorInsulin
Affiliated Institutions
Related Publications
Update on Nonalcoholic Fatty Liver Disease
Nonalcoholic fatty liver disease is now recognized as the most common liver disease in the United States, with a prevalence of approximately 5% in the general population and up ...
Nonalcoholic Fatty Liver: A Possible New Target for Type 2 Diabetes Prevention and Treatment
Non-alcoholic fatty liver disease (NAFLD) is the most common liver disorder worldwide. Several lines of evidence have indicated a pathogenic role of insulin resistance, and a st...
A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis† ‡
Nonalcoholic steatohepatitis (NASH) is a common chronic liver disease for which there is no known effective therapy. A proportion of patients with NASH progress to advanced fibr...
Mechanisms and disease consequences of nonalcoholic fatty liver disease
Nonalcoholic fatty liver disease (NAFLD) is the leading chronic liver disease worldwide. Its more advanced subtype, nonalcoholic steatohepatitis (NASH), connotes progressive liv...
Nonalcoholic Fatty Liver, Steatohepatitis, and the Metabolic Syndrome
Nonalcoholic fatty liver disease (NAFLD) has been associated with the insulin–resistance syndrome, at present defined as the metabolic syndrome, whose limits were recently set. ...
Publication Info
- Year
- 2015
- Type
- review
- Volume
- 35
- Issue
- 03
- Pages
- 338-348
- Citations
- 32
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
32
OpenAlex
Cite This
Samer Gawrieh,
Naga Chalasani
(2015).
Pharmacotherapy for Nonalcoholic Fatty Liver Disease.
Seminars in Liver Disease
, 35
(03)
, 338-348.
https://doi.org/10.1055/s-0035-1562951
Identifiers
- DOI
- 10.1055/s-0035-1562951